Neutrophil

• Food can affect how well your lungs function, how often you have asthma attacks and how well your puffer works.
• Here’s what we know about which foods to eat more of, and which are best to eat in smaller amounts, if you have asthma.

Asthma and inflammation

• This makes it difficult for them to breathe during what’s commonly known as an asthma attack (or exacerbation).
• Researchers are becoming increasingly aware of how someone’s diet can affect their asthma symptoms, including how often they have one of these attacks.
• Read more:
  Passive smoking, synthetic bedding and gas heating in homes show the strongest links to asthma

Thumbs up for fruit and veg

• The Mediterranean diet – a diet high in fruit, vegetables and oily fish – is linked with less wheezing in children, whether or not they have been diagnosed with asthma.
• Some, but not all, of the studies found this was regardless of the children’s body-mass index (BMI) or socioeconomic status.
• However a review looked at five studies that investigated omega-3 intake (through the diet or with a supplement) in adults with asthma.
• Of course there is no harm in eating foods high in omega-3 – such as oily fish, flaxseeds, chia seeds and walnuts.

Thumbs down for saturated fat, sugar, red meat

• Diets high in saturated fats, plus sugar and red meat, can worsen someone’s asthma symptoms.
• Foods high in saturated fat can have an impact in as little as four hours.
• People who ate the meal high in saturated fat had reduced lung function within four hours.

What about dairy?

One food type you don’t have to avoid, though, is dairy products. Although many people with asthma report eating dairy worsens their asthma, evidence shows this to be untrue. In fact, one study in adults with asthma found drinking milk was linked to better lung function.

Read more:
Monday's medical myth: dairy products exacerbate asthma

• London, 6 July 2023 –LIfT BioSciences, (‘LifT’ or ‘the Company’), a rapidly emerging biotech company bringing to market a first-in-class allogeneic innate cell therapy, today announced successful proof-of-concept production of its patented cancer killing alpha neutrophils from induced pluripotent stem cells (iPSCs).
• Alex Blyth, Chief Executive Officer of LIfT BioSciences, commented: “Our goal is to develop a scalable and cost-effective off-the-shelf cell therapy that can be used in all cancer patients without the ongoing need for stem cell donors.
• Our patented production process is pretty simple compared to other cell therapies, with no feeder cells or expensive magnetic bead enrichment being required.
• It is therefore incredibly exciting that our IMANs, which we have designed to overcome many of the challenges with other cell therapies, can now also be made with an even lower cost of goods from iPSCs.

• DENVER, June 20, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces enrollment of the first patient in the NEUTRALIZE-AKI pivotal clinical trial to evaluate the safety and efficacy of its patented, first-in-class, cell-directed Selective Cytopheretic Device (SCD) extracorporeal therapy in critically ill adults with acute kidney injury (AKI) requiring continuous kidney replacement therapy (CKRT).
• “We are delighted to enroll the first patient into our pivotal trial following the successful resolution of a supply-chain issue that temporarily impacted the sourcing of tubing connectors that are part of the SCD sets,” said Kevin Chung, MD, Chief Medical Officer of SeaStar Medical.
• “Nearly two dozen hospitals and academic centers have signed on to begin the process of onboarding as clinical trial sites.
• These sites are at various stages of activation with several anticipated to begin enrollment very soon.”
  “We believe that reprogramming activated neutrophils and monocytes represents a major breakthrough for managing hyperinflammation in acute illness.

• As 5G infrastructure becomes more mainstream, enterprises and organizations are subsequently deploying more private networks and telco clouds into strategic locations to leverage newly available connectivity, lower latency, and agility.
• F5, a hybrid and multi-cloud application services and security company, deployed carrier-grade BIG-IP Virtual Editions .
• These security functions were consolidated with an N6/SGi-LAN solution adding another layer of speed and security at the network level.
• Finally, the entire solution was pressure-tested through technology made available through the 5G OI Lab and its enterprise and operator partners deployed with GXC’s ONYX Portal.